Bristol-Myers Squibb Company (BMY)
Bristol-Myers Squibb: No Respect For Blowout Earnings - Buy The Richer Dividend Yields
BMY's double-beat FQ2'25 performance and raised FY2025 guidance have been met with much skepticism, as observed in the steep pullback post earnings. This is despite the Growth Portfolio comprising over 50% of its overall revenues, with further expansion likely thanks to its intensified R&D, partnerships, and M&A efforts. BMY's discounted valuations present a deep-value buying opportunity, with patient investors well rewarded with rich dividend yields, pending growth acceleration.
Bristol-Myers Q2 Earnings Review: Solid Quarter, But Incoming CMO Must Fix Pipeline
Bristol-Myers Squibb Company beat Q2 2025 revenue expectations and raised full-year guidance, but EPS guidance was lowered and shares remain under pressure. The company's growth portfolio is expanding, but heavy reliance on Eliquis and Opdivo, both facing patent expiries, clouds the outlook. Key upcoming data catalysts and a new CMO offer hope, yet recent drug launches and acquisitions have underperformed expectations.
Bristol-Myers Squibb: Growth Is Taking Its Own Time (Rating Downgrade)
Bristol-Myers Squibb's Q2 2025 results were a mixed bag, with revenues showing signs of recovery while earnings saw a pullback. A reduction in earnings guidance on IPRD charges was another disappointment, though early signs of the performance of acquired treatment Cobenfy are positive. Underwhelming earnings since last year, along with revenues that are still coming back in form could explain the loss of price momentum for BMY despite otherwise healthy stock metrics.
Bristol-Myers Squibb Company (BMY) Q2 2025 Earnings Call Transcript
Bristol-Myers Squibb Company (NYSE:BMY ) Q2 2025 Earnings Conference Call July 31, 2025 8:00 AM ET Company Participants Adam Lenkowsky - Executive VP & Chief Commercialization Officer Christopher S. Boerner - CEO & Chairman Chuck Triano - Corporate Participant David V.
Bristol Myers (BMY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Bristol Myers (BMY) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Bristol Myers Squibb (BMY) Q2 Earnings and Revenues Top Estimates
Bristol Myers Squibb (BMY) came out with quarterly earnings of $1.46 per share, beating the Zacks Consensus Estimate of $1.07 per share. This compares to earnings of $2.07 per share a year ago.
How Will Bristol Myers Squibb Stock React To Its Upcoming Earnings?
Bristol Myers Squibb (NYSE:BMY) is scheduled to release its earnings report on Thursday, July 31, 2025. For event-driven traders, examining historical stock performance around earnings announcements can provide valuable insights.
Will Collaboration With Bain Capital Help BMY Advance Its Pipeline?
Bristol Myers partners with Bain Capital to launch a new autoimmune-focused biotech, out-licensing five key immunology assets.
Bristol Myers Squibb and Bain Capital Form New Immunology Company
The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which will retain 20% equity in the new company.
Should You Buy, Hold, or Sell BMY Stock Ahead of Q2 Earnings?
BMY gears up for Q2 results as growth drugs partially offset legacy declines, cost cuts kick in and new launches gain traction. We recommend investors to wait and watch for now.
Bristol Myers Gains 6.3% in a Month: Buy, Sell or Hold the Stock?
BMY rises 6.3% in a month as investors pin hopes on new drugs to offset pressure from pipeline and patent losses.
Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for
Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
